ReviewAcute medicine & surgery
Gut dysbiosis and its treatment in patients with critical illness.
Review in Acute medicine & surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Gut Microbiome Dysbiosis in Atopic Dermatitis: Pathogenic Mechanisms, Gut-Skin Axis Disruption, and Emerging Microbiota-Targeted Therapies.Biomedicines · 2026Review
- Early Gut Microbiome-Short-Chain Fatty Acid Axis Disruption May Be Associated with Delayed Recovery in Critically Ill Children.Nutrients · 2026Observational
- Prognostic prediction in COVID-19 patients: a comprehensive analysis of gut microbiota and hematological biomarkers.Virus research · 2026Article
- The high-risk phenotype for gastrointestinal vulnerability in sepsis and 28-day mortality: an integrative study based on clinical association and cross-level biological support.Frontiers in medicine · 2026Article
- Ferroptosis in vascular injury of critically ill patients: implications of gut microbiota regulation.Frontiers in cellular and infection microbiology · 2026Review
- Gut microbiota dysbiosis in sepsis: mechanisms and the gut-organ axis with a focus on lung and brain interactions.Frontiers in microbiology · 2026Review
- Gut microbiota dysbiosis in sepsis and sepsis-associated organ injury: mechanisms, gut-organ axes, and therapeutic strategies.Frontiers in microbiology · 2026Review
- Gut dysbiosis and its treatment in patients with critical illness.Acute medicine & surgeryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut is a target organ that functions as the "motor" of critical illness. In patients with critical illness, the disrupted gut microbiota following infection and injury could cause diarrhea, pneumonia, and systemic inflammation. For maintaining the gut microbiota, therapeutic approaches are required to modulate host responses and prevent systemic inflammation. Probiotics and synbiotics could maintain the gut microbiota and decrease not only the incidence of diarrhea but also that of ventilator-associated pneumonia. The effects of probiotics/synbiotics differ with the type of bacteria and disease severity. Adverse effects of probiotics have been reported; therefore, the selection of safe and effective probiotics/synbiotics is warranted. Refractory diarrhea with prolonged dysbiosis may require a novel intestinal therapy, such as fecal microbiota transplantation, to alleviate gut dysbiosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.